November 18, 2006Open Access

Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This regimen has anti-NB activity, spares vital organs, is feasible with poor bone marrow reserve, causes limited immunosuppression, and allows good quality of life.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Kushner et al. (Sat,) studied this question.

synapsesocial.com/papers/69dc8ae7a5c75be4cfe52f55 https://doi.org/https://doi.org/10.1200/jco.2006.06.7272

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma2005 · 196 citations
2Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors2004 · 138 citations
3Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.1998 · 95 citations
4Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.1999 · 225 citations
5Phase I study of temozolomide in paediatric patients with advanced cancer1998 · 139 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo